Early toxicity predicts long-term survival in high-grade glioma

Br J Cancer. 2011 Apr 26;104(9):1365-71. doi: 10.1038/bjc.2011.123. Epub 2011 Apr 12.

Abstract

Background: Patients with high-grade gliomas are treated with surgery followed by chemoradiation. The risk factors and implications of neurological side effects are not known.

Methods: Acute and late ≥ grade 3 neurological toxicities (NTs) were analysed among 2761 patients from 14 RTOG trials accrued from 1983 to 2003. The association between acute and late toxicity was analysed using a stepwise logistic regression model. The association between the occurrence of acute NT and survival was analysed as an independent variable.

Results: There were 2610 analysable patients (86% glioblastoma, 10% anaplastic astrocytoma). All received a systemic agent during radiation (83% chemotherapy, 17% biological agents). Median radiation dose was 60 Gy. There were 182 acute and 83 late NT events. On univariate analysis, older age, poor performance status, aggressive surgery, pre-existing neurological dysfunction, poor mental status and twice-daily radiation were associated with increased acute NT. In a stepwise logistic regression model the occurrence of acute NT was significantly associated with late NT (OR=2.40; 95% CI=1.2-4.8; P=0.014). The occurrence of acute NT predicted poorer overall survival, independent of recursive partitioning analysis class (median 7.8 vs 11.8 months).

Interpretation: Acute NT is significantly associated with both late NT and overall survival.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adult
  • Aged
  • Analysis of Variance
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Chemotherapy, Adjuvant / adverse effects
  • Dacarbazine / administration & dosage
  • Dacarbazine / adverse effects
  • Dacarbazine / analogs & derivatives*
  • Dose Fractionation, Radiation
  • Female
  • Glioma / drug therapy
  • Glioma / pathology*
  • Glioma / radiotherapy
  • Glioma / surgery
  • Glioma / therapy*
  • Humans
  • Incidence
  • Logistic Models
  • Male
  • Middle Aged
  • Radiotherapy, Adjuvant / adverse effects
  • Retrospective Studies
  • Risk Factors
  • Supratentorial Neoplasms / drug therapy
  • Supratentorial Neoplasms / pathology*
  • Supratentorial Neoplasms / radiotherapy
  • Supratentorial Neoplasms / surgery
  • Supratentorial Neoplasms / therapy*
  • Survival Analysis
  • Temozolomide
  • Time Factors

Substances

  • Antineoplastic Agents
  • Dacarbazine
  • Temozolomide